AUP1 inhibitors constitutes a distinct group of organic compounds that modulate the enzymatic activity of AUP1 (ancient ubiquitous protein 1). AUP1 plays a pivotal role in cellular lipid droplet biology, acting as a key regulator in both the formation and degradation of lipid droplets, which are crucial organelles involved in lipid storage and cellular energy homeostasis. Inhibitors within this class are thoughtfully engineered to interact with specific binding sites on the AUP1 protein, thereby influencing its functional roles in cellular lipid metabolism. The development and exploration of AUP1 inhibitors require a comprehensive approach, encompassing molecular modeling, structural analyses, and in-depth investigations into the molecular interactions between these inhibitors and the AUP1 enzyme. This multifaceted strategy aims to optimize the inhibitors for increased specificity towards AUP1, heightened potency, and improved compatibility within the cellular environment. A profound understanding of the structural intricacies of AUP1 and its role in lipid droplet dynamics is essential for the rational design of effective inhibitors within this chemical class.
The primary objective driving the investigation and design of AUP1 inhibitors is to unravel the molecular intricacies governing lipid droplet regulation mediated by AUP1. These inhibitors serve as essential tools for dissecting the mechanisms through which AUP1 influences lipid storage, turnover, and related cellular processes. By selectively inhibiting AUP1, researchers aim to uncover the precise molecular mechanisms that underlie lipid droplet dynamics. The ongoing refinement and exploration of AUP1 inhibitors are essential for advancing our understanding of cellular lipid metabolism and the fundamental processes that govern lipid droplet biology. Through the elucidation of AUP1 inhibition, scientists gain a deeper appreciation for the intricate molecular mechanisms driving lipid droplet formation and degradation within cells, revealing new insights into the broader cellular significance of AUP1 and its influence on lipid-related cellular functions.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
N-Ethylmaleimide | 128-53-0 | sc-202719A sc-202719 sc-202719B sc-202719C sc-202719D | 1 g 5 g 25 g 100 g 250 g | $22.00 $69.00 $214.00 $796.00 $1918.00 | 19 | |
A widely-used compound that can modify cysteine residues, NEM has been reported to inhibit AUP1 activity in the context of ER-associated protein degradation. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $78.00 $260.00 | 18 | |
A compound primarily used as an antineoplastic agent, hydroxyurea has been reported to inhibit AUP1. | ||||||
Atglistatin | 1469924-27-3 | sc-503147 | 5 mg | $330.00 | ||
Initially identified as a selective inhibitor of adipose triglyceride lipase (ATGL), atglistatin has been suggested to indirectly influence AUP1 due to its involvement in lipid metabolism pathways. | ||||||
Gallotannin | 1401-55-4 | sc-202619 sc-202619A sc-202619B sc-202619C sc-202619D sc-202619E sc-202619F | 1 g 10 g 100 g 250 g 1 kg 2.5 kg 5 kg | $26.00 $37.00 $67.00 $78.00 $234.00 $536.00 $983.00 | 12 | |
A naturally occurring polyphenol with diverse biological activities, tannic acid has been studied for its potential to inhibit ER-associated degradation, which may involve AUP1. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
Although known as an inhibitor of autophagy, 3-MA might also impact lipid metabolism pathways, potentially affecting AUP1-regulated processes. | ||||||
Salicylic acid | 69-72-7 | sc-203374 sc-203374A sc-203374B | 100 g 500 g 1 kg | $47.00 $94.00 $119.00 | 3 | |
A compound with anti-inflammatory properties, salicylic acid has been suggested to have effects on ER-associated degradation, which could potentially involve AUP1. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
A compound known to disrupt ER calcium homeostasis, thapsigargin has been reported to impact ER-associated degradation, potentially affecting AUP1. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A widely-used proteasome inhibitor, MG-132 can indirectly influence AUP1 activity by modulating ER-associated degradation pathways. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
A compound that disrupts protein glycosylation in the ER, tunicamycin has been suggested to impact ER-associated degradation, potentially involving AUP1. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
A compound known to activate adenylate cyclase, forskolin has been studied for its impact on lipid metabolism pathways, which may indirectly affect AUP1. | ||||||